Welcome to our dedicated page for Clearside Biomed news (Ticker: CLSD), a resource for investors and traders seeking the latest updates and insights on Clearside Biomed stock.
Clearside Biomedical, Inc. (CLSD) is a biopharmaceutical company that focuses on delivering therapies to the back of the eye through the suprachoroidal space (SCS®). News about CLSD frequently centers on its patented SCS injection platform, its commercial product XIPERE® for uveitic macular edema, and its lead development program CLS-AX (axitinib injectable suspension) for neovascular age-related macular degeneration (wet AMD).
Investors and observers following CLSD news can expect updates on clinical data from Phase 1/2a and Phase 2b trials of CLS-AX, regulatory interactions such as End-of-Phase 2 meetings and Phase 3 program planning, and preclinical work on small molecule programs targeting geographic atrophy and diabetic macular edema. Company announcements also highlight scientific presentations at major ophthalmology meetings, including ARVO, EURETINA, and other retinal-focused conferences, where Clearside and its collaborators discuss suprachoroidal delivery, trial designs, and platform-related technologies.
Clearside’s news flow also includes developments from its licensing and collaboration partners. These items may cover regulatory approvals and filings for XIPERE or ARCATUS® in various territories, progress in partner-led clinical programs using the SCS Microinjector, and updates on gene therapy or anti-tumor agents delivered via the suprachoroidal route. Corporate and financial updates, such as quarterly results, strategic review announcements, reverse stock split actions, royalty monetization agreements, and Nasdaq listing compliance matters, are also part of the company’s regular disclosures.
More recently, CLSD news has included its decision to explore strategic alternatives for its SCS platform and pipeline, and the subsequent voluntary Chapter 11 filing in the U.S. Bankruptcy Court for the District of Delaware with the stated objective of pursuing a sale of substantially all assets. For users tracking CLSD, this news page provides a centralized view of clinical, regulatory, partnership, and restructuring developments affecting the company and its stock.
Clearside Biomedical, Inc. (NASDAQ:CLSD) has announced the enrollment of the first patients in its Phase 1/2a clinical trial for CLS-AX, a novel axitinib injectable suspension for treating wet age-related macular degeneration (AMD). The trial, named OASIS, aims to assess the safety and tolerability of CLS-AX via suprachoroidal injection. The study will include 15 patients across 3 cohorts with varying dosage levels. Positive preclinical results indicate that CLS-AX could alleviate treatment burdens compared to existing therapies. Initial data is expected in mid-2021.
Clearside Biomedical (NASDAQ:CLSD) has announced a securities purchase agreement with institutional investors for the sale of 4,209,050 shares of common stock at $2.851 per share, totaling approximately $12.0 million in gross proceeds. This registered direct offering is priced based on the five-day average closing price and is expected to close on January 8, 2021. Roth Capital Partners is the sole placement agent for the offering, which is part of a previously filed shelf registration statement with the SEC.
Clearside Biomedical (Nasdaq: CLSD) announced two presentations of its preclinical and clinical data at the virtual AAO 2020 Annual Meeting. A recent publication highlights the clinical characterization of a suprachoroidal injection procedure across three retinal disorders. Dr. Thomas A. Ciulla noted the success of 33 presentations throughout the year and the anticipated data from CLS-AX in 2021. The platform is designed for targeted, compartmentalized delivery of ocular therapies, including ongoing partnerships that feature Clearside's SCS Microinjector for gene therapy and melanoma.
Clearside Biomedical, a biopharmaceutical company focused on vision restoration treatments, will present a company overview at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 8:40 a.m. ET. The presentation will be accessible via a live webcast on the Clearside website, with an archived version available for three months. Clearside specializes in innovative approaches to treat serious back of the eye diseases using their proprietary SCS Microinjector technology, which allows targeted delivery of treatments.
Clearside Biomedical (NASDAQ:CLSD) announced the initiation of a Phase 1/2a trial for CLS-AX aimed at treating wet age-related macular degeneration (AMD) by year-end 2020. The company reported Q3 2020 financial results, showing license revenue of $3.4 million, a significant increase from $141,000 in Q3 2019, mainly due to a partner milestone payment. Research expenses rose to $3.5 million, partly due to preparations for CLS-AX, while the net loss decreased to $2.4 million, or $0.05 per share. Clearside expects to have sufficient resources to fund operations into Q3 2021.
Clearside Biomedical (NASDAQ:CLSD) will report its third quarter 2020 financial results on November 10, 2020, after market close. A webcast and conference call are scheduled for 4:30 PM ET for discussions on these results and corporate updates. Clearside specializes in treatments aimed at restoring vision for patients with serious eye diseases, utilizing a flexible, non-surgical SCS Microinjector® to deliver targeted therapies.
Clearside Biomedical (Nasdaq: CLSD) announced clinical data presentations at the 53rd Annual Scientific Meeting of The Retina Society, highlighting its investigational drug, XIPERE™, in a Phase 2 trial for diabetic macular edema (DME). The trial suggests XIPERE may reduce treatment burden if approved. The company also plans to initiate a Phase 1/2a trial for CLS-AX in wet AMD this year. Data presented includes positive tolerability results for CLS-AX and promising outcomes for suprachoroidal injections, potentially establishing Clearside's innovative approach in retinal disease therapies.
Clearside Biomedical (NASDAQ:CLSD) announced that its leadership team, including President George Lasezkay and CMO Thomas Ciulla, will provide a company overview at the Virtual H.C. Wainwright 22nd Annual Global Investment Conference on September 16, 2020, at 11:30 a.m. ET. The presentation will focus on Clearside's innovative treatments aimed at restoring vision for individuals with serious back-of-the-eye diseases. Interested parties can access the live and archived webcast through the company's website under the Investors section for three months.
Clearside Biomedical (NASDAQ: CLSD) announced the issuance of three additional patents in the U.S. and Europe, bolstering its intellectual property portfolio, particularly for the SCS Microinjector. The U.S. Patent No. 10,722,396, expiring in 2034, covers the administration of axitinib. European patents include one for a device for therapeutic administration, expiring in 2031, and another for XIPERE™ treatment, expiring in 2033. With 21 U.S. and 20 European patents, Clearside aims to advance its pipeline, including three product candidates anticipated in clinical trials by year-end.
Clearside Biomedical (NASDAQ:CLSD) reports key updates and financial results for Q2 2020. The FDA accepted its IND application for CLS-AX (axitinib injectable suspension), marking a significant step in its suprachoroidal pipeline expansion. Clearside initiated two new preclinical programs and partnered with a new manufacturer for XIPERE, enhancing production efficiency. Despite a net loss of $5.8 million for Q2, up from $5.7 million, the company believes it has adequate cash resources to sustain operations until mid-2021, supported by its licensing revenue growth to $0.4 million.
FAQ
What is the current stock price of Clearside Biomed (CLSD)?
What is the market cap of Clearside Biomed (CLSD)?
